ArticleJournal of pharmacy & bioallied sciences2026
Assessment of Different Treatment Modalities for the Treatment of Oral Lichen Planus.
Article in Journal of pharmacy & bioallied sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Global prevalence of Oral lichen planus is estimated to be 1.01% and 0.49% in Indian context with more predilection for females. A number of factors relating to emotional stability and personality modulation is associated with development of OLP. Patients often relate onset or an exacerbation of their condition to stressful life events. Despite different treatment modalities in use, corticosteroids are still the first line treatment option followed by tacrolimus and curcumin for oral lichen planus, which is a chronic disease with episodes of recurrence and remission. Methodology: 105 patients were divided into groups of 35 each to receive either triamcinolone acetonide (0.1%), tacrolimus (0.03%), or oral nanocurcumin (500 mg). The patients applied the medication twice daily or took oral preparation twice daily. The patients were followed at 15 days, 1 month, 3 months and after completion of treatment at 6 months and 1 year. Assessment of the appearance score and severity of pain was done and recorded in the patients' questionnaires. Results: Inter-time comparison of burning sensation between three groups based on treatment modalities showed statistically significant results. Patients in the triamcinolone and tacrolimus groups showed faster rate of healing than nanocurcumin while Nanocurcumin group showed slow rate of healing but there was no relapse at 12-month followup. Decrease in clinical symptoms and burning sensation were seen in all the three groups. Conclusion: Nanocurcumin can be used for maintenance phase after initial symptomatic treatment of oral lichen planus by conventional treatment modalities. Limitation: Further studies with a longer regimen period and follow-up is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.